# Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

> **NCT04843774** · — · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 64 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** SARS-COV-2 mRNA Vaccine

## Key facts

- **NCT ID:** NCT04843774
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-20
- **Primary completion:** 2023-04-18
- **Final completion:** 2023-04-18
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04843774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04843774, "Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04843774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*